Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURATION: Durlaza in CVD Patients with High Platelet Turnover
NCT02370680Phase 1Completed
- Sponsor
- New Haven Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of aspirin in cardiovascular disease (CVD) (2 arms), sponsored by New Haven Pharmaceuticals. Primary endpoint: Change in platelet aggregation at 24 hours. Started Feb 2015; status: completed.
02
Drugs
aspirin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02370680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370680.